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Abstract The harmony and function of the complex brain
circuits and synapses are sustained mainly by excitatory
and inhibitory neurotransmission, neurotrophins, gene
regulation, and factors, many of which are incompletely
understood. A common feature of brain circuit components,
such as dendrites, synaptic membranes, and other mem-
branes of the nervous system, is that they are richly
endowed in docosahexaenoic acid (DHA), the main
member of the omega-3 essential fatty acid family. DHA
is avidly retained and concentrated in the nervous system
and known to play a role in neuroprotection, memory, and
vision. Only recently has it become apparent why the
surprisingly rapid increases in free (unesterified) DHA pool
size take place at the onset of seizures or brain injury. This
phenomenon began to be clarified by the discovery of
neuroprotectin D1 (NPD1), the first-uncovered bioactive
docosanoid formed from free DHA through 15-
lipoxygenase-1 (15-LOX-1). NPD1 synthesis includes, as
agonists, oxidative stress and neurotrophins. The evolving
concept is that DHA-derived docosanoids set in motion
endogenous signaling to sustain homeostatic synaptic and
circuit integrity. NPD1 is anti-inflammatory, displays
inflammatory resolving activities, and induces cell sur-
vival, which is in contrast to the pro-inflammatory actions
of the many of omega-6 fatty acid family members. We
highlight here studies relevant to the ability of DHA to
sustain neuronal function and protect synapses and circuits
in the context of DHA signalolipidomics. DHA sig-
nalolipidomics comprises the integration of the cellular/
tissue mechanism of DHA uptake, its distribution among
cellular compartments, the organization and function of
membrane domains containing DHA phospholipids, and the
precise cellular and molecular events revealed by the
uncovering of signaling pathways regulated by docosanoids
endowed with prohomeostatic and cell survival bioactivity.
Therefore, this approach offers emerging targets for
prevention, pharmaceutical intervention, and clinical trans-
lation involving DHA-mediated signaling.
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The availability of omega-3 essential fatty acids (FAs) in the
Western diet has dramatically decreased during the last
several decades. The health consequences of this shift in the
diet on brain diseases are underestimated. The global burden
of alcohol and drug dependence, depression, dementia, and
several other mental and neurological diseases is greater
than that of cancer and cardiovascular disease [1]. Because
docosahexaenoic acid (DHA; 22:6, n-3), a major member of
the omega-3 FA family, accumulates and is avidly retained
in central nervous system (CNS) membranes (mainly
synapses, dendrites, and photoreceptors), the impact of this
fatty acid on synaptic function and circuitry integrity is
incompletely understood.
Here, we provide an overview of the evolving knowl-
edge on cellular and molecular mechanisms of DHA action.
DHA plays a major role in neuroprotection, memory, and
vision. Therefore, to unravel its significance, DHA
signalolipidomics [2] represents a comprehensive ap-
proach that includes the cellular/tissue organization of
DHA uptake, its distribution among cellular compart-
ments, the organization and function of membrane
domains rich in DHA-containing phospholipids, and
molecular pathways regulated by DHA-derived bioactive
lipids (docosanoids), which include neuroprotectin D1
(NPD1), a novel DHA-derived stereoselective mediator
[2]. One aspect relevant to nutrition and addiction we
discuss here is that when hippocampal circuitry is
challenged with successive subconvulsive electrical stim-
ulations to generate an epileptic state, it is restored
toward physiological conditions by NPD1 [3]. The
i m p l i c a t i o ni st h a tN P D 1b i o a c t i v i t yi ns e i z u r e so rt h e
initial stages of neurodegenerative diseases offers an
innovative approach involving DHA signaling and opens
a new set of questions relevant to the modulation of
homeostatic synaptic and circuit integrity.
DHA is Essential in Human Nervous System
Development and Function
DHA supply is required during pre- and post-natal
development to build functionally critical brain circuits.
Synaptogenesis, dentrite formation, photoreceptor mem-
brane biogenesis, and biogenesis of other neural mem-
branes take place during early post-natal development.
The phospholipids of these membranes are richly
endowed with DHA. Linolenic acid (LA; 18:3, n-3),
another essential fatty acid, leads to DHA synthesis
through a series of elongation and desaturation steps. In
humans, dietary supplies of LA are not able to cope with
the needs of the nervous system. In fact, dietary DHA
itself is needed to fulfill the developmental demands of
the nervous system [4]. A shortage of DHA during the
pre- and post-natal developmental stage usually results
from a dietary shortage of maternally provided DHA in
the placenta and breast milk [1]. DHA supply to the
nervous system is required throughout life in much smaller
proportions because of the tenacity through which this
fatty acid is retained. In pathological conditions, DHA loss
due to peroxidation may enhance its requirements. For
example, a substantial loss of DHA has been observed in
Alzheimer's disease (AD) brains [5].
The omega-6 fatty acid family is also essential and gives
rise to arachidonic acid (AA; 20:4, n-6), which in turn is
widely distributed in tissues and serves as the precursor of
eicosanoids. Both AA and DHA compete for several of the
enzymes that catalyze elongation and desaturation.
DHA, unlike AA, is enriched in the nervous system. Both
families of essential fatty acids are ultimately required from
the diet.
DHA is Supplied by the Liver for Synaptogenesis
and Neural Membrane Biogenesis
Dietary linolenic acid is elongated and desaturated into
DHA in the liver. The liver takes up dietary DHA, uses it
for the biosynthesis of phospholipids, and then distrib-
utes these lipids to tissues in the CNS. This liver-to-CNS
route is upregulated during pre- and post-natal develop-
ment, when neural cells and their circuits are built.
Strikingly, labeled omega-3s injected into developing
rodents first appeared in the liver and decreased
subsequently in a time-dependent manner, whereas
labeled DHA evolved and appeared esterified to phos-
pholipids and triglycerides; furthermore, rats intravenous-
ly infused with labeled alpha-linolenic acid (ALA) for
2 h confirmed the ability of the liver to supply DHA to
the brain and showed the appearance of esterified DHA
in a sigmoidal time-dependent manner [6–8]. This was
concurrent with the decrease of labeled ALA in plasma.
These studies allowed for mathematical modeling of
liver synthesis and secretion rates of DHA from plasma
ALA. By using positron emission tomography scans
together with radio-tracer studies, relative incorporation
rates have been estimated for humans and experimental
animals. In healthy 15-week-old rats, liver conversion of
ALA to DHA surpassed the brain consumption rate 30-
fold [7, 9, 10]. Similar studies in humans confirmed the
liver's ability to provide physiologically adequate amounts
of DHA when ALA was present in the diet [10]. The
hepatic conversion of ALA to DHA in healthy individuals
is sufficient to meet the demands of DHA in the brain and
retina [8, 11] .T h er e l a t i v es i g n i f i c a n c eo fL At of u l f i l lt h e
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been put into perspective [4].
The hypothesis that the brain directs DHA release from
the liver, likely as DHA phospholipids in lipoproteins [11,
12] and in the form of brain/retina-to-liver signaling,
remains to be tested. Since DHA is so critical to brain
and retina function, and since its availability depends on the
diet, conservation mechanisms assure its supply and
retention. In the retina and intercellular loop, DHA
retention is assured during the daily, massive exit of DHA
phospholipids from photoreceptor tips during photoreceptor
cell renewal [2, 13, 14]. A large supply of DHA
accumulates in the liver during the biogenesis of mem-
branes in the nervous system, and signals more than likely
evoke the release of this fatty acid from the liver when
necessary, such as during DHA loss in neurodegenerative
diseases [11]. Moreover, nutritional studies addressing
DHA supply to the nervous system must take into
consideration the period when the study is performed and
its duration. During post-natal development, rapid DHA
uptake occurs; however, once DHA is taken up by nervous
tissue, smaller amounts are required.
Neuroprotectin D1 and the Free Pool
of Docosahexaenoic Acid
The brain, photoreceptors, and retinal pigment epithelial
(RPE) cells display an undetectable quantity of unesterified
(free) DHA (as is the case with unesterified arachidonic
acid) under basal, non-stimulated conditions [15–17]. This
indicates that the pool size of unesterified DHA is tightly
controlled by phospholipase A2 (PLA2), reacylation, and by
peroxidation (under some conditions). Free DHA, incorpo-
rated into membrane phospholipids, first becomes the
substrate of docosahexaenoyl-coenzyme A synthesis for
channeling through acyltransferases, which incorporate this
FA into phospholipids [18].
RPE cells modulate the uptake, conservation, and
delivery of DHA to photoreceptors [19]. Cells actively
modulate the free DHA pool size in vitro when DHA is
added in micromolar concentrations. The selectivity of the
effects studied under these conditions, as well as the non-
specific response and potential toxicity, need to be assessed.
RPE cells use a specific DHA-phospholipid pool as a
precursor for NPD1 synthesis, and the selective oxygena-
tion of DHA by 15-lipoxygenase-1 (15-LOX-1) leads to
NPD1 synthesis [20]. Oxidative stress, neurotrophins,
ischemia/reperfusion, amyloid-beta (Aβ) 42 and beta-
amyloid precursor protein (βAPP) are all inducers of
NPD1 synthesis, but the molecular details of this induction
are not completely understood. Figure 1 outlines the uptake
of DHA from the bloodstream and its distribution in
astrocytes and neurons. Several of the routes depicted are
still hypothetical.
NPD1 bioactivity triggers homeostatic/pro-survival signal-
ing in response to cellular and systemic insults [5, 13, 21].
Specifically, NPD1 upregulates anti-apoptotic proteins (Bcl-2
and Bcl-xL) and downregulates pro-apoptotic proteins (Bax
and Bad) in response to cellular oxidative stress and cytokine
activation, leading to an overall pro-survival transcriptome
[5, 13, 21, 22]. NPD1 also provides a specific mechanism to
understand DHA-mediated modulation of neuroinflamma-
tion and neuroprotection. Moreover, NPD1 elicits neuro-
protection in brain ischemia/reperfusion and in oxidative-
stressed retinal cells [21–23], and it inhibits retinal ganglion
cell death [24]. NPD1 is also protective in kidney ischemia/
reperfusion [25] and regulates adiponectin [26]. DNA
microarray profiling shows downregulation of pro-
inflammatory genes as well as of pro-apoptotic genes of
the Bcl-2 gene family [5]; thus, NPD1 is a stereo-specific
mediator that executes protective bioactivity of DHA in the
CNS. Deficiency of NPD1 and of the enzyme involved in its
formation, 15-LOX-1, has been observed in AD brain [5].
Also, NPD1 further influences βAPP processing and
decreases Aβ42 release [5]. DHA, the precursor of NPD1,
elicits an Aβ42-lowering effect both in vitro and in vivo
[27–29]. In addition, free radical-mediated DHA peroxida-
tion products accumulate during ischemia and neurodegen-
eration. In turn, these oxidation products may form protein
adducts and other cytotoxic molecules that promote further
free radical injury [30–32].
DHA-NPD1 Significance in Epileptogenesis
Epileptogenesis affects circuits and neurotransmissions,
leading to aberrant connections and spontaneous seizures.
Seizures induce enhancements in free DHA at the synapses
[33]. The below subsections summarize studies undertaken
to understand the significance of DHA and NPD1 in a
model of epileptogenesis.
Seizures Evoke Neuroprotectin D1 Synthesis in the
Hippocampus Systemic administration of DHA enhan-
ces NPD1 synthesis at the onset of generalized seizures
in the hippocampus [3], the region most affected by
limbic seizures and critical to controlling seizure propa-
gation. NPD1 synthesis is initiated by the release of DHA
through PLA2 f o l l o w e db y1 5 - L O X - 1[ 20, 34]. Seizure-
induced early activation of NPD1 synthesis suggests
induction of endogenous mechanism/s that might be
involved in control of seizure development and reduc-
tion or prevention of brain damage. Also, small
increases in NPD1 occur in the ipsilateral frontal cortex
and brain stem, indicating neural circuits that are
218 Mol Neurobiol (2011) 44:216–222activated during the progression from partial to gener-
alized seizures [3].
Neuroprotectin D1 Attenuates Hippocampal Epileptiform
Activity and Progression of Motor Seizures In a model of
temporal lobe epilepsy [3, 35, 36], NPD1 or its precursor,
DHA, reduced seizure severity and duration of epileptiform
activity in the hippocampus [3]. NPD1 alone limited
progression of severe motor seizures and modified
seizure-evoked morphology, as represented by spikes
followed by small amplitude polyspikes [3]. NPD1 also
modulated different phases of the epileptiform discharges
[3, 35], suggesting involvement of a homeostatic excitato-
ry–inhibitory mechanism in hippocampal circuitry. Since
DHA is actively converted into NPD1 as a consequence of
seizures, this lipid mediator may be responsible for DHA
bioactivity in experimental epilepsy [37].
Neuroprotectin D1 Attenuates Hippocampal Hyperexcitabil-
ity and Seizure Spread NPD1 attenuates hippocampal
hyperexcitability at least 1 week after kindling acquisi-
tion [3], revealing its effective modification of kindling
progression through an excitability mechanism related
with the spread of seizures. Thus, NPD1 or DHA may
control the spread of seizures through a mechanism more
closely related with epileptogenesis [3]t h a ni c t i o g e n e s i s
[38]. Glutamate transporter 1 (GLT1), glutamate aspartate
transporter (GLAST), and excitatory amino acid trans-
porter 1 (EAAC1) are modulated by DHA [39], suggesting
that this fatty acid regulates glutamate availability at the
synapses through glutamate transporters. Impaired gluta-
mate uptake occurs in experimental models of epilepsy
and epileptic patients; as a consequence, glutamate is
elevated during induction and propagation of seizures
[40]. On the other hand, DHA regulates gamma-
aminobutyric acid (GABA) receptor subunits [41]; as a
result, the imbalance of the excitatory–inhibitory mecha-
nisms during seizures may be restored by NPD1. Also,
NPD1 may attenuate hippocampal hyperexcitability by
limiting cellular inflammatory responses in the brain.
In addition, both astrocytes [42] and cytokines are major
participants in epileptogenesis [43, 44]. Cytokine-mediated
activation of pro-inflammatory signaling is downregulated
by NPD1 [22], which is consistent with other models of
brain damage/neuroinflammation [21] and retinal models of
oxidative stress [5, 13, 22, 45].
Fig. 1 Movement of docosahex-
aenoic acid (DHA) (22:6)
through the neurovascular unit
and its disposition within neu-
rons and astrocytes. 22:6-Phos-
pholipids (22:6-PLs) are taken up
by endothelial cells from the
circulation and transferred to
astrocytes within the central ner-
vous system; from there, 22:6 is
incorporated into astrocytes or
transferred to neurons. 22:6 is
also available for conversion to
neuroprotectin D1 (NPD1) upon
inductive signals. After packag-
ing in the endoplasmic reticulum
and the Golgi apparatus, 22:6 is
also transported to the synaptic
terminal to become incorporated




remains to be done. Reprinted,
with permission, from the Annu-
al Review of Nutrition, Volume
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Pre-mitochondrial Steps of the Apoptotic Cascade
In addition to the above-described events, NPD1 induces
cell survival. This is mediated by actions on Bcl-2 proteins
at pre-mitochondrial steps of the apoptotic cascade. The
serine/theonin protein phosphatase, protein phosphatase 2A
(PP2A), dephosphorylates Bcl-2 family proteins [46–48].
PP2A has catalytic (C-subunit), structural (A-subunit), and
regulatory (B-subunit) subunits. The A and B subunits are
ubiquitously expressed and evolutionarily conserved. The B
subunit targets the catalytic complex (AC) to microtubules,
the nucleus, or the cytoplasm [49, 50]. PP2A is the main
phosphatase that dephosphorylates Bad [48], resulting in
apoptosis. The catalytic subunit of PP2A alone is sufficient
to dephosphorylate Bcl-2 [50] and Bax, and thus can help
reduce or prevent cell death [51].
NPD1 induces dephosphorylation of S62Bcl-xL, and
studies regarding this uncovered a mechanism to control the
expression of anti- and pro-apoptotic factors in response to
oxidative stress [51]. Bcl-xL phosphorylation in RPE cells is
induced by oxidative stress, and NPD1 enhances PP2A
activity, in turn downregulating oxidative stress-induced
phosphorylation of the anti-apoptotic protein Bcl-xL. There-
fore, NPD1 is a regulator of the PP2A/C/Bcl-xL interaction,
which suggests a stimulus-specific response in NPD1-
dependent phosphorylation of Bcl-xL. NPD1 modulates the
activation of this Bcl-2 family member by modifying the
phosphorylation status in a PP2A-dependent manner and also
by facilitating the interaction of its counterpart pro-apoptotic
proteinBax, pointingto a highly coordinated,NPD1-mediated
regulation of cell survival in response to oxidative stress [52].
Outlook
The study of DHA signalolipidomics will continue to
unravel the significance of lipids containing DHA in brain
function. Membrane lipids in synapses and neuronal circuits
are richly endowed with DHA, and it is therefore of the
utmost importance to investigate the effectiveness of the
dietary supply of this and other fatty acids, as well as the
potential effects of their supplementation, on brain function.
Due to the identification of bioactive DHA mediators,
mainly NPD1, we can now begin resolving the fundamental
question of how DHA contributes to brain function.
Recently, DHA signalolipidomics and nutrition were
reviewed in regards to function and diseases of the nervous
system [2]. One example of how the study of DHA
signalolipidomics can be applied is in studying the involve-
ment of the dopaminergic system in addiction. Do deficits in
dietary availability of omega-3 essential fatty acids enhance
addictive behavior/s? Does nutrition selectively modify
dopaminergic neurotransmission? Does nutrition also modify
other neurotransmitter systems? Are there interactions
between omega-3 fatty acids and endocannabinoids? What
are the consequences of nutritional DHA deficits? Are there
alternative events, since key nervous system functions are
supported by redundant mechanisms? Will dietary supple-
mentation be sufficient? These are just a few questions DHA
signalolipidomics can address in a myriad of evolving issues.
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